Research Institute of Molecular Pathology

The Research Institute of Molecular Pathology (IMP) is a basic biomedical research center sponsored largely by the pharmaceutical company Boehringer Ingelheim, and located in the Campus Vienna Biocenter (VBC). The IMP's primary goal is to conduct innovative basic research in the molecular life sciences. Over the years, the IMP has rapidly established a strong international reputation, reflected in the numerous national and international awards bestowed upon its scientists, and the many key research papers published in top-ranking scientific journals each year. The IMP attracts researchers from all over the world, almost all of whom move on after several years to leading scientific positions elsewhere in Austria or abroad. This constant turnover gives the IMP a young, dynamic and international spirit, and the flexibility to continually hire promising new scientific talents and expand its research activities into exciting new directions. Researchers at the IMP are committed to basic science, striving to unlock life's fundamental mysteries at the molecular and cellular levels.

Address
Campus-Vienna-Biocenter 1
Website
https://www.imp.ac.at

Subscribe to rss feed

Vaccination

The WTO waiver battle over Covid jab IP rights

Sudden US backing for a global waiver on patent protections for COVID-19 vaccines offers hope to poor nations struggling for doses—but the big pharma industry thinks the notion misguided.

Business

Microsoft pledges to store European cloud data in EU

US tech giant Microsoft pledged Thursday to process and store all European cloud-based client data in the European Union amid unease in the region over the reach of US legislation on personal data collection.

Vaccination

World mulls next step as US backs IP waiver on vaccines

Activists cheered, Big Pharma complained and government leaders assessed next steps on Thursday after the Biden administration's blockbuster move to support an easing of patent and other protections on COVID-19 vaccines that ...

Business

Google says 20% of workers will be remote, many more hybrid

Google says it expects about 20% of its workforce to still work remotely after its offices reopen this fall, while some 60% will work a hybrid schedule that includes about three days in the office and two days "wherever they ...

page 1 from 2